Progress toward a neutralizing antibody-based HIV vaccine — ASN Events
  1. Schedule
  2. Bazeley Oration
  3. Progress toward a neutralizing antibody-based HIV vaccine

Progress toward a neutralizing antibody-based HIV vaccine (#1)

Dennis Burton 1 2
  1. Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, United States of America
  2. Dept of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States

Highly antigenically variable viruses such as HIV present major problems for vaccine design. Broadly neutralizing antibodies to HIV generated during natural infection can identify weaknesses in the surface structures of the virus. These weaknesses can help guide vaccine and drug design and reveal fascinating aspects of the interplay between two highly mutable systems-the virus and antibody

#2018ASM